Therapeutic implications of osteoprotegerin

Cancer Cell International

Volumn 9, Issue , 2009, Pages 26-

  Fili, Sofia ^a   Karalaki, Maria ^a   Schaller, Bernhard ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ORADEA   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DENOSUMAB; DEOXYPYRIDINOLINE; DICKKOPF 1 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD VESSEL CALCIFICATION; BONE METASTASIS; BONE PAIN; BONE REMODELING; BREAST CANCER; BREAST CARCINOMA; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SPECIFICITY; DRUG TARGETING; FRACTURE; HUMAN; HYPERCALCEMIA; LOW DRUG DOSE; MULTIPLE MYELOMA; NONHUMAN; ORTHOPEDIC SURGERY; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RENAL OSTEODYSTROPHY; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

EID: 70449380416     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-9-26     Document Type: Review

References (70)

1. Fili S, Karalaki M, Schaller B. Mechanisms of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer Lett 2009, 283:10-9. 10.1016/j.canlet.2009.01.011, 19201081.
2. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-kB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clinical Endocrinol Metab 2007, 92:4514-21.
3. Ulrich-Vinther M, Soeballe K, Andreasen TT. Effects of osteoprotegerin treatment on healing fractures. Bone 2005, 37:751-8. 10.1016/j.bone.2005.07.021, 16169783.
4. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JWM, Ryan PFJ, Dunstan CR, Martin TJ, Gillespie MT. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427. 1867274, 12368214.
5. Schaller B, Merlo A, Kirsch E, Lehmann K, Huber PR, Lyrer P, Steck AJ, Gratzl O. Prostate-specific antigen in the cerebrospinal fluid leads to diagnosis of solitary cauda equina metastasis: A unique case report and review of the literature. Br J Cancer 1998, 77:2386-9. 2150374, 9649164.
6. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006, 12:17-25. 10.1016/j.molmed.2005.11.007, 16356770.
7. Degli-Esposti Mariapia To die of not to die- the quest of the TRAIL receptors. Journal of leukocyte biology 1999, 65:535-542.
8. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clinical Science 2006, 110:279-291. 10.1042/CS20050175, 16464170.
9. Emery J, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273:14363-14367. 10.1074/jbc.273.23.14363, 9603945.
10. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002, 62:1619-23.
11. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?. Breast Cancer Res Treat 2005, 92:207-215. 10.1007/s10549-005-2419-8, 16155791.
12. Shipman CM, Croucher PI. Osteoprotegerin is a solube decoy receptor fot tumor necrosis factor- related apoptosis- inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003, 63:912-916.
13. Schaller B, Cornelius JF, Sandu N. Molecular medicine successes in neuroscience. Mol Med 2008, 14:361-4. 10.2119/2008-00055.Schaller, 2464323, 18496586.
14. Honore P, Luger NM, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, O'keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Medicine 2000, 6:521-528. 10.1038/74999, 10802707.
15. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664. 10.1056/NEJMra030831, 15084698.
16. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176. 10.1053/ctrv.2000.0210, 11417967.
17. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature 2002, 2:584-493.
18. Petrut B, Simmons C, Broom R, Trinkaus M, Clemons M. Pharmacotherapy of bone metastases in breast cancer patients. Expert Opin Pharmacother 2008, 9:937-45. 10.1517/14656566.9.6.937, 18377337.
19. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22:549-553. 10.1161/01.ATV.0000012303.37971.DA, 11950689.
20. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD. A phase I study of AMGN-0007 a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 1:887-892.
21. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I. Osteoprotegerin (opg) produced by bone marrow stromal cells protects breast cancer cells from trail-induced apoptosis. Breast Cancer Research and Treatment 2004, 86:269-279. 10.1023/B:BREA.0000036900.48763.b3, 15567943.
22. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221-1228. 10.1158/1078-0432.CCR-05-1933, 16489077.
23. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer induced osteoclastogenesis and prevents tumor growth in the bone. J Clin Invest 2001, 107:1235-1244. 10.1172/JCI11685, 209296, 11375413.
24. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008, 7:2160-9. 10.1158/1535-7163.MCT-08-0046, 18606716.
25. Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL. Human bone marrow stromal cells protect prostate cancer cells from TRAIL- induced apoptosis. J Bone Miner Res 2004, 19:1712-1721. 10.1359/JBMR.040703, 15355567.
26. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. Osteoprotegerin in prostate cancer bone metastases. Cancer Res 2005, 65:1710-1718. 10.1158/0008-5472.CAN-04-2033, 15753366.
27. Ando K, Mori K, Rédini F, Heymann D. RANKL/RANK/OPG; key therapeutic target in bone oncology. Curr Drug Discov Technol 2008, 5:263-268. 10.2174/157016308785739857, 2661019, 18690894.
28. Mori K, Ando K, Heymann D, Rédini F. Receptor activator of nuclear factor- kappa B ligand (RANKL) stimulates bone- assosiated tumors through functional RANK expressed on bone- assosiated cancer cells. Histol Histopathol 2009, 24:235-242.
29. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001, 57:611-616. 10.1016/S0090-4295(00)01122-5, 11306358.
30. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANK/RANKL/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006, 107:289-298. 10.1002/cncr.21978, 16752412.
31. Park HR, Min SK, Cho HD, Kim DH, Shin HS, Park YE. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J Korean Med Sci 2003, 18:541-546.
32. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432-6.
33. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008, 25:119-29. 10.1007/s10585-007-9127-1, 18064531.
34. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005, 16:1223-1231. 10.1093/annonc/mdi235, 15928069.
35. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 15:3534-40.
36. Croucher PI, Shipman CM, Van Camp B, Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 2003, 97:818-24. 10.1002/cncr.11125, 12548581.
37. Guiliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98:3527-3533. 10.1182/blood.V98.13.3527, 11739153.
38. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR. Serum osteoprotegerin levels in healthy controls and cancer patient. Clin Cancer Res 2002, 8:2306-10.
39. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ. A phase I study of AMGN- a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 0007, 97:887-892.
40. Guiliani N, Colla S, Rizzoli V. Update on the pathogenesis of osteolysis in multiple myeloma patients. Acta Bio Medica Ateneo Parmense 2004, 75:143-152.
41. Oyajobi MO. Multiple myeloma/hypercalcemia. Arthritis Res ther 2007, 9(supp l):S4.
42. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E. Dickkopf- 1: a suitable target for managment of myeloma bone disease. Expert Opin Ther Targets 2009, 13:839-848. 10.1517/14728220903025770, 19530987.
43. Goltzman D. Osteolysis and cancer. J Clin Invest 2001, 107:1219-1220. 10.1172/JCI13073, 209307, 11375409.
44. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000, 60:783-787.
45. Martin TJ. Hypercalcemia of malignancy epidemiology and pathogenesis. Clinical Review in Bone and Mineral Metabolism 2002, 1:51-64.
46. Hamdy NAT. Osteoprotegerin as a potential therapy for osteoporosis. Current Rheumatology Reports 2006, 8:50-54. 10.1007/s11926-006-0026-2, 16515766.
47. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-30. 152939, 12697741.
48. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001, 142:4295-4304. 10.1210/en.142.10.4295, 11564687.
49. Bolon B, Carter C, Daris M, Morony S, Campagnuolo G, Feige U, Sheng J. Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease. Arthritis Res 2001, 3:5.
50. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-70. 10.1210/en.140.9.4367, 10465311.
51. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348-360. 10.1359/jbmr.2001.16.2.348, 11204435.
52. Coetzee M, Kruger MC. Osteoprotegerin-receptor activator of nuclear factor-[kappa]B ligand ratio: A new approach to osteoporosis treatment?. South Med J 2004, 97:506-11. 10.1097/00007611-200405000-00018, 15180028.
53. Humphrey E, Williams J, Davie M, Marshall M. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006, 38:652-61. 10.1016/j.bone.2005.10.004, 16298558.
54. Nobuhiro S, Eiji K, Yasuhiro A, Kazuki Y, Eisuke T. Glucocorticoid decreases circulating osteoprotegerin (OPG): Possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant n 2001, 16(3):479-482. 10.1093/ndt/16.3.479.
55. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E, Asano Y. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 2002, 30:853-8. 10.1016/S8756-3282(02)00742-1, 12052453.
56. Lubberts E, Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003, 170:2655-62.
57. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-53. 10.1002/art.10388, 12124857.
58. Catrina AI, Af Klint E, Ernestam S, Catrina S, Makrygiannakis D, Botusan I, Klareskog L, Ulfgren AK. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006, 54:76-81. 10.1002/art.21528, 16385498.
59. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-9. 10.1038/46303, 10580503.
60. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E. Serum osteoprotegerin and renal osteodystriphy. Nephrol Dial Transplant 2002, 17:233-238. 10.1093/ndt/17.2.233, 11812872.
61. Fukagawa M, Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 2002, 17:2-5. 10.1093/ndt/17.9.1553, 12386262.
62. Collin-Osbody P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046-1057. 10.1161/01.RES.0000149165.99974.12, 15564564.
63. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204:321-329. 10.1016/j.atherosclerosis.2008.09.033, 19007931.
64. Schaller B. Reply to "dissection of the internal carotid artery and hemicraniectomy. Am J Med 2007, 120:e17. 10.1016/j.amjmed.2005.12.033, 17275437.
65. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM. RANKL increases vascular smooth muscle cell calcification through a RANKL-BMP4- dependent pathway. Circ Res 2009, 104:1041-1048. 10.1161/CIRCRESAHA.108.189001, 19325147.
66. Tintut Y, Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Investig Med 2006, 54:395-401. 10.2310/6650.2006.06019, 17169261.
67. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin- deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268. 10.1101/gad.12.9.1260, 316769, 9573043.
68. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and vitamin D. Arterioscler Thromb Vasc Biol 2001, 21:1610-1616. 10.1161/hq1001.097102, 11597934.
69. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008, 159:603-608. 10.1530/EJE-08-0554, 18697793.
70. Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009, 204:608-611. 10.1016/j.atherosclerosis.2008.10.024, 19062016.